Clinical Trial Focuses on Treatment of Sepsis

TWIN FALLS, Idaho -- Medical Discoveries, Inc. announces its receipt of the first in a series of pre-clinical reports from Dr. Emil Chi, chairman of the department of histopathology at the University of Washington Medical

School, for one of several studies on models of infectious diseases mimicking human infectious disease. It focused on MDI-P as a potential therapeutic agent for the treatment of sepsis. The results reaffirmed the anti-infective strength and low toxicity profile in preclinical models of MDI's patented solution, MDI-P.

The novel drug was applied to a mouse model of sepsis, to examine any

effect on this fatal bacterial infection. Sepsis is an infection of the

internal organs and generally occurs in patients during prolonged hospital

stays for surgery, pneumonia, or for treatment of wounds. This infection

carries a high risk of leading to septic shock of the internal organs and

death of the patient who has been infected. Sepsis is a leading cause of

death in intensive care units worldwide.

In this study, the goal was to test the efficacy of MDI-P in inhibiting

inflammatory responses induced in mice by the Psuedomonas aeurginosa bacterium

that frequently causes sepsis. The study used 25 percent, 50 percent and 100 percent MDI-P solutions to examine inhibition of inflammatory processes, as it is these

processes that generally lead to widespread bacterimia, followed potentially

by septic shock. MDI-P was compared against both a saline control group of

mice, as well as a positive control group of mice that had been given a

powerful antibiotic, Gentamicin, an established treatment for sepsis in

pre-clinical studies.

The study confirmed that the 100 percent dose strength of MDI-P offered

substantial benefit to the mice when compared both to placebo and a

50 percent survival effect comparable to Gentamicin, but without the apparent

toxicity profile that Gentamicin exhibits. All doses of MDI-P provided

substantial benefit in reducing inflammatory response of the bacterimia, but

only the 100 percent strength provided a host-sparing effect.

MDI's CEO, Judy Robinett, commented, "We are pleased

that MDI-P, our patented solution, continues to show powerful anti-infective

characteristics without associated toxicities, both in-vivo and in-vitro.

This report, in addition to other preclinical reports and our CMC/CGMP data,

will allow us to file an IND with the FDA for our initial target indication,

HIV, and enter clinical trials sometime late in 2004 or early in 2005,

continuing the path to commercialization."

Formed in 1991, Medical Discoveries, Inc. is a development-stage biopharmaceutical research company engaged in the research, development and

validation of its patented anti-infective technology.

Source: Medical Discoveries, Inc.